Current Report Filing (8-k)
February 15 2023 - 08:01AM
Edgar (US Regulatory)
0000764195 false VBI Vaccines Inc/BC
0000764195 2023-02-15 2023-02-15 iso4217:USD xbrli:shares
iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
February 15, 2023
VBI VACCINES INC.
(Exact
name of registrant as specified in its charter)
|
British Columbia, Canada |
|
001-37769 |
|
N/A |
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
|
160 Second Street,
Floor 3
Cambridge,
Massachusetts
|
|
02142 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4© under the Exchange Act (17
CFR 240.13e-4©) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of exchange on which registered |
|
Common Shares, no par value per share |
|
VBIV |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
February 15, 2023, VBI Vaccines Inc. (the “Company”) issued a press
release announcing interim data from the Phase 2 study evaluating
the combination of VBI-2601 (BRII-179), the Company’s HBV
immunotherapeutic candidate, and BRII-835 (VIR-2218), an
HBV-targeting siRNA candidate, in chronically infected HBV
patients. The Company undertakes no obligation to update,
supplement or amend the materials attached hereto.
The
information in this Current Report on Form 8-K (including Exhibit
99.1 attached hereto) is being furnished pursuant to Item 7.01 and
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise be subject to the liabilities of that section, nor
shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof and regardless of any
general incorporation language in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
VBI
Vaccines Inc. |
|
|
|
|
Date:
February 15, 2023 |
By: |
/s/
Jeffrey R. Baxter |
|
|
|
Jeffrey
R. Baxter |
|
|
|
President
and Chief Executive Officer |
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Sep 2023 to Oct 2023
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Oct 2022 to Oct 2023
